Strides subsidiary Arco Lab completes full acquisition of Neviton Softech
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Arco Lab, wholly owned subsidiary of Strides Pharma, acquired the remaining 50 percent stake in Neviton Softech from Romanian firm UACD for about Rs 21.77 crores (Euro 2 million). Neviton is now a wholly owned step-down subsidiary effective Feb 16, 2026. Neviton offers IoT and IT engineering services, with FY25 revenue of Rs 27.08 crores and PAT of Rs 4.26 crores. Arco Lab earlier held 50 percent from buys in 2022 and 2024.
Small tuck-in acquisition via subsidiary; Neviton becomes wholly owned, boosting internal IT and digitisation capability. Limited direct impact on group earnings.